Why IRLA Stock surged +4.21% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, IRLA scores 33 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 7 out of 20, reflecting an ROIC of -35% and an FCF yield of -12.19%, which indicates the business is consuming rather than generating cash on a per-dollar-of-capital basis. The whale 13F flow pillar scores 6 out of 20, based on institutional accumulation and options positioning, signaling limited smart-money conviction. The insider conviction pillar scores 3 out of 20, the lowest of the five, drawn from SEC Form 4 and Congressional PTR cluster flow. The macro regime fit pillar scores 7 out of 20, with a beta of 1.0 and sector sensitivity noted. The forensic balance sheet pillar scores 10 out of 20, with an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and a Debt/Equity ratio of 0.5.

For a prospective investor evaluating the stock today, the rating points toward downside risk concentrated in the cash-flow and insider-conviction pillars. The forensic balance sheet metrics, particularly the Piotroski F-Score of 1 out of 9, indicate weak financial-health signals across the fundamentals checklist. Any upside case would need to rest on factors outside the reported cash engine, which the source data does not establish. This analysis is educational and not personalized financial advice.

IRulya Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company carries a market capitalization of $0.3B. Per the recent news wire, the company was formerly known as Quince Therapeutics and has repositioned toward pulmonary and lung disease drug development. The source data does not describe specific products, customers, or revenue model beyond reporting zero revenue in the financials.

Per the SEC financials, reported revenue is $0.0M across all three periods, with operating losses widening from $-34.6M in FY 2023 to $-58.1M in FY 2025 and net losses from $-31.4M to $-84.0M. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1 out of 9, with a Debt/Equity ratio of 0.5. Reported cash declined from $6.2M in FY 2024 to $5.8M in FY 2025 against negative free cash flow of $-41.8M in FY 2025.

Per the recent news wire, the headline catalyst is the rename from Quince Therapeutics to IRulya Therapeutics, described as advancing pulmonary drug development after a merger. A Fierce Pharma item characterizes the relaunch as going all in on lung disease following what it calls a Hail Mary merger. Six items all carry a YELLOW light and a MARKET WIRE impact label, and the summaries are generic market-action descriptions rather than verifiable event detail. Recurring themes are the name change, lung-disease focus, and merger context. Risk watch items include the absence of revenue, widening losses, and the thin cash balance relative to annual cash burn shown in the financials. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.

• What is the company's cash runway given FY 2025 free cash flow of $-41.8M against reported cash of $5.8M?
• What were the terms and financial impact of the merger referenced in the news wire, and how does it affect the balance sheet?
• Which clinical or regulatory milestones underpin the pulmonary pipeline, and what is their timing?
• Why are FY 2023 cash and debt figures, and FY 2024 and FY 2025 debt, not reported in the source data?
• What explains the 52-week range of $15.1 to $910, which the source data does not reconcile with the current price of 31.62?